Literature DB >> 22479221

Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex.

Jennifer Cawood.   

Abstract

Two new biologics for HCV present treatment and cost-management challenges.

Entities:  

Year:  2011        PMID: 22479221      PMCID: PMC3278124     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN: 1554-169X


  4 in total

1.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

2.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

3.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

4.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

  4 in total
  1 in total

1.  Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection.

Authors:  Terence N Bukong; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2013-09-17       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.